Via an oversubscribed private placement, Medigene AG has obtained more than EUR 32 million on Friday morning. Through accelerated bookbuilding, Medigene issued 2,230,000 million new shares from authorized capital - approximately 10% of its current share capital. The shares were placed with institutional investors at a price of € 14.50 per share, representing a discount of 2.3% at the closing price. The proceeds of the transaction will be used to expand the company's program into TCR-based T cell immunotherapy. In this area, Medigene is working in several cooperation programs for the US company Bluebird Bio, which had recently extended this cooperation to 6 projects running (see News).
Dr. Thomas Taapken, CFO of Medigene, was pleased with the high demand: "In addition to the existing institutional shareholders, we were able to attract new, health-focused investors. We are grateful for this strong vote of confidence in Medigene as a world leader in T-cell immunology. "
see www.medigene.com for further information.